Cypress Capital Group Gilead Sciences, Inc. Transaction History

Cypress Capital Group

$879 Million
Q3 2024

A detailed history of Cypress Capital Group transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cypress Capital Group holds 50,284 shares of GILD stock, worth $4.59 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares

50,284

Previous 50,919 1.25%

Holding current value

$4.59 Million

Previous $3.49 Million 20.64%

% of portfolio

0.48%

Previous 0.42%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$66.59 - $83.99 $42,284 - $53,333	-635 Reduced 1.25%	50,284 $4.21 Million
Q2 2024 Jul 25, 2024	SELL	$63.15 - $72.88 $5,620 - $6,486	-89 Reduced 0.17%	50,919 $3.49 Million
Q1 2024 May 08, 2024	SELL	$71.58 - $87.29 $28,560 - $34,828	-399 Reduced 0.78%	51,008 $3.74 Million
Q4 2023 Jan 24, 2024	SELL	$73.27 - $83.09 $355,359 - $402,986	-4,850 Reduced 8.62%	51,407 $4.16 Million
Q3 2023 Nov 02, 2023	SELL	$73.94 - $80.67 $133,239 - $145,367	-1,802 Reduced 3.1%	56,257 $4.22 Million
Q2 2023 Jul 26, 2023	SELL	$76.01 - $86.7 $256,229 - $292,265	-3,371 Reduced 5.49%	58,059 $4.47 Million
Q1 2023 May 04, 2023	SELL	$77.31 - $88.08 $947,511 - $1.08 Million	-12,256 Reduced 16.63%	61,430 $5.1 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $5,546 - $7,962	-89 Reduced 0.12%	73,686 $6.33 Million
Q3 2022 Nov 04, 2022	BUY	$59.54 - $68.01 $58,468 - $66,785	982 Added 1.35%	73,775 $4.55 Million
Q2 2022 Jul 26, 2022	BUY	$57.72 - $65.01 $429,725 - $483,999	7,445 Added 11.39%	72,793 $4.5 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $723,073 - $906,088	12,484 Added 23.62%	65,348 $3.89 Million
Q4 2021 Feb 15, 2022	BUY	$64.88 - $73.64 $618,111 - $701,568	9,527 Added 21.98%	52,864 $3.84 Million
Q3 2021 Oct 12, 2021	SELL	$67.69 - $73.03 $65,253 - $70,400	-964 Reduced 2.18%	43,337 $3.03 Million
Q2 2021 Jul 13, 2021	SELL	$63.47 - $69.35 $19,866 - $21,706	-313 Reduced 0.7%	44,301 $3.05 Million
Q1 2021 Apr 14, 2021	BUY	$60.0 - $68.46 $57,060 - $65,105	951 Added 2.18%	44,614 $2.88 Million
Q4 2020 Jan 12, 2021	SELL	$56.65 - $64.55 $117,605 - $134,005	-2,076 Reduced 4.54%	43,663 $2.54 Million
Q3 2020 Oct 08, 2020	SELL	$62.1 - $78.08 $596,346 - $749,802	-9,603 Reduced 17.35%	45,739 $2.89 Million
Q2 2020 Jul 10, 2020	BUY	$72.34 - $84.0 $561,286 - $651,756	7,759 Added 16.31%	55,342 $4.26 Million
Q1 2020 Apr 08, 2020	BUY	$62.63 - $80.22 $234,110 - $299,862	3,738 Added 8.53%	47,583 $3.56 Million
Q4 2019 Jan 10, 2020	SELL	$61.62 - $67.78 $94,278 - $103,703	-1,530 Reduced 3.37%	43,845 $2.85 Million
Q3 2019 Oct 10, 2019	SELL	$62.51 - $69.0 $58,009 - $64,032	-928 Reduced 2.0%	45,375 $2.88 Million
Q2 2019 Aug 15, 2019	BUY	$61.87 - $69.38 $106,230 - $119,125	1,717 Added 3.85%	46,303 $3.13 Million
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $210,413 - $235,718	-3,365 Reduced 7.02%	44,586 $2.9 Million
Q4 2018 Feb 19, 2019	SELL	$60.54 - $79.0 $174,476 - $227,678	-2,882 Reduced 5.67%	47,951 $3 Million
Q3 2018 Nov 15, 2018	BUY	$71.28 - $78.92 $713,797 - $790,304	10,014 Added 24.53%	50,833 $3.93 Million
Q2 2018 Aug 15, 2018	SELL	$64.88 - $75.68 $193,342 - $225,526	-2,980 Reduced 6.8%	40,819 $2.89 Million
Q1 2018 May 21, 2018	BUY	$72.84 - $88.8 $190,913 - $232,744	2,621 Added 6.37%	43,799 $3.3 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $75,917 - $89,115	-1,067 Reduced 2.53%	41,178 $2.95 Million
Q3 2017 Nov 16, 2017	BUY	$72.11 - $85.47 $36,055 - $42,735	500 Added 1.2%	42,245 $3.42 Million
Q2 2017 Aug 15, 2017	BUY	N/A	41,745	41,745 $2.96 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cypress Capital Group, based on Form 13F filings with the SEC.

News

Stay updated on Cypress Capital Group with notifications on news.

Account

Cypress Capital Group Gilead Sciences, Inc. Transaction History